CONSOLIDATED STATEMENTS OF CONTINGENTLY REDEEMABLE COMMON STOCK AND STOCKHOLDERS EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	IPO	Contingently Redeemable Common Stock	Contingently Redeemable Common Stock IPO	Common Stock	Common Stock IPO	Additional Paid-in Capital	Additional Paid-in Capital IPO	Retained Earnings	Noncontrolling Interest
Beginning balance at Dec. 31, 2018	$ 41,596				$ 2,454		$ 247,237		$ (208,550)	$ 455
Beginning balance, shares at Dec. 31, 2018					245,421
Contingently Redeemable Common Stock, Beginning balance, shares at Dec. 31, 2018			26,444
Contingently Redeemable Common Stock, Beginning balance at Dec. 31, 2018			$ 100,000
Net income (loss)	(282,740)								(282,588)	(152)
Issuance of contingently redeemable common stock	(806)						(806)
Issuance of contingently redeemable common stock, shares			43,416
Issuance of contingently redeemable common stock, value			$ 181,000
Settlement of stock-based liabilities	5,000				$ 13		4,987
Settlement of stock-based liabilities, Shares					1,322
Stock-based compensation expense	5,225						5,225
Distribution to noncontrolling interests	(303)									(303)
Contingently Redeemable Common Stock, Ending balance, shares at Dec. 31, 2019			69,860
Contingently Redeemable Common Stock, Ending balance at Dec. 31, 2019			$ 281,000
Ending balance at Dec. 31, 2019	(232,028)				$ 2,467		256,643		(491,138)	0
Ending balance, shares at Dec. 31, 2019					246,743
Net income (loss)	$ (60,052)								(60,052)
Issuance of common stock, shares	1,200				1,235
Issuance of common stock, value	$ 5,550				$ 13		5,537
Issuance of contingently redeemable common stock	(460)						(460)
Issuance of contingently redeemable common stock, shares			6,341
Issuance of contingently redeemable common stock, value			$ 28,500
Settlement of stock-based liabilities	1,500				$ 3		1,497
Settlement of stock-based liabilities, Shares					334
Repurchase of common stock	$ (6,742)				$ (15)		(6,727)
Repurchase of common stock, shares	(1,500)				(1,500)
Exercises and vesting of stock-based awards	$ 814				$ 26		788
Exercises and vesting of stock-based awards, Shares					2,562
Stock-based compensation expense	$ 6,688						6,688
Contingently Redeemable Common Stock, Ending balance, shares at Dec. 31, 2020	76,201		76,201
Contingently Redeemable Common Stock, Ending balance at Dec. 31, 2020	$ 309,500		$ 309,500
Ending balance at Dec. 31, 2020	$ (284,730)				$ 2,494		263,966		(551,190)	0
Ending balance, shares at Dec. 31, 2020	249,374				249,374
Net income (loss)	$ (406,787)								(406,487)	(300)
Reclassification of contingently redeemable common stock in connection with IPO, shares				(76,201)		76,201
Reclassification of contingently redeemable common stock in connection with IPO, value		$ 309,500		$ (309,500)		$ 762		$ 308,738
Issuance of common stock, shares						53,590
Issuance of common stock, value		1,163,133				$ 536		1,162,597
Issuance of common stock under partner physician group equity agreements upon IPO, shares						11,672
Issuance of common stock under partner physician group equity agreements upon IPO, value		$ 268,467				$ 117		$ 268,350
Exercises and vesting of stock-based awards	18,086				$ 92		17,994
Exercises and vesting of stock-based awards, Shares					9,258
Stock-based compensation expense	23,927						23,927
Contingently Redeemable Common Stock, Ending balance at Dec. 31, 2021	0
Ending balance at Dec. 31, 2021	$ 1,091,596				$ 4,001		$ 2,045,572		$ (957,677)	$ (300)
Ending balance, shares at Dec. 31, 2021	400,095				400,095